MktsMarkets

Intellia Therapeutics, Inc.
NASDAQ: NTLAKey statistics
NTLA News
Stories mentioning NTLA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 15,048 | 23,017 | 13,782 | 14,245 | 16,627 | 12,874 | 9,111 | 6,957 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 80,737 | 88,652 | 94,747 | 97,035 | 108,427 | 116,877 | 123,380 | 114,207 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (100,532) | (98,710) | (111,477) | (109,996) | (120,807) | (136,447) | (144,770) | (139,043) |
| Interest Income | 5,205 | 6,476 | 6,714 | 7,402 | 8,603 | 10,631 | 12,122 | 12,422 |
| Interest Expense | ||||||||
| Other Expense | 4,301 | 2,924 | 10,153 | 8,741 | 6,478 | 7,549 | 9,058 | (7,932) |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (96,231) | (95,786) | (101,324) | (101,255) | (114,329) | (128,898) | (135,712) | (146,975) |
| Earnings Per Share (Basic) | (0.81) | (0.88) | (0.92) | (0.98) | (1.10) | (1.30) | (1.34) | (1.52) |
| Earnings Per Share (Diluted) | (0.81) | (0.88) | (0.92) | (0.98) | (1.10) | (1.30) | (1.34) | (1.52) |
| Weighted Average Shares Outstanding (Basic) | 118,490 | 108,376 | 110,188 | 103,732 | 103,500 | 98,849 | 101,002 | 96,975 |
| Weighted Average Shares Outstanding (Diluted) | 118,490 | 108,376 | 110,188 | 103,732 | 103,500 | 98,849 | 101,002 | 96,975 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About NTLA
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a stock listed on the Nasdaq Stock Market under the ticker symbol NTLA. It last traded at $10.00 (Nov 20, 2026, 4:00 PM ET), up 5.0% on the day. That gives Intellia Therapeutics a market capitalisation of $1.4B.
Over the past 52 weeks NTLA has traded between $7.95 and $18.48.
Revenue for the quarter ended Mar 31, 2026 was $15.0M; a net loss of $96.2M. Revenue was down 9.5% from $16.6M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $15.0M | -$96.2M | -639.5% |
| Dec 31, 2025 | $23.0M | -$95.8M | -416.2% |
| Sep 30, 2025 | $13.8M | -$101.3M | -735.2% |
| Jun 30, 2025 | $14.2M | -$101.3M | -710.8% |
From Intellia Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…